Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Barchart Premier: The most comprehensive method for keeping track of all your investments. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Evotec Se (EVTCY)

Evotec Se (EVTCY)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]

Fundamentals

See More
  • Market Capitalization, $K 7,581,874
  • Shares Outstanding, K 330,221
  • Annual Sales, $ 572,210 K
  • Annual Income, $ 7,140 K
  • 60-Month Beta 0.98
  • Price/Sales 13.26
  • Price/Cash Flow 105.48
  • Price/Book 7.36
Trade EVTCY with:
  • Price/Earnings ttm 56.02
  • Earnings Per Share ttm 0.40
  • Most Recent Earnings N/A on N/A
  • Latest Earnings Date 11/11/21
  • Annual Dividend & Yield 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Price Performance

See More
Period Period Low Period High Performance
1-Month
22.5944 +1.62%
on 10/07/21
26.5700 -13.59%
on 10/21/21
-0.8025 (-3.38%)
since 09/29/21
3-Month
21.0925 +8.85%
on 08/04/21
26.5700 -13.59%
on 10/21/21
+2.6475 (+13.03%)
since 08/02/21
52-Week
14.2225 +61.43%
on 11/10/20
26.5700 -13.59%
on 10/21/21
+9.4575 (+70.04%)
since 11/03/20

Most Recent Stories

More News
Evotec Receives € 3 m Milestone Payment for Bayer Starting Phase II Clinical Development of DNP Programme

- FIRST DOSING OF A STUDY PARTICIPANT TRIGGERS MILESTONE PAYMENT OF € 3 M TO EVOTEC - PHASE II CLINICAL TRIAL INITIATED BY EVOTEC'S PARTNER BAYER TO EVALUATE BAY 2395840 AS A POTENTIAL TREATMENT FOR...

EVTCY : 22.9600 (-0.04%)
EVO : 5.08 (-2.87%)
Evotec Enters iPSC-based Drug Discovery Partnership with Boehringer Ingelheim in Ophthalmology

- PARTNERSHIP LEVERAGES EVOTEC'S HUMAN IPSC-BASED PHENOTYPIC SCREENING AND PANOMICS PLATFORMS - AIM IS TO IDENTIFY AND VALIDATE PROMISING TARGETS AND NEW APPROACHES FOR THERAPEUTIC INTERVENTIONS HAMBURG,...

EVTCY : 22.9600 (-0.04%)
EVO : 5.08 (-2.87%)
Evotec and Lilly Enter into Drug Discovery Collaboration in Metabolic Diseases

- COLLABORATION LEVERAGES EVOTEC'S BROAD METABOLIC EXPERTISE AND UNIQUE KIDNEY DISEASE PATIENT DATABASE AS WELL AS INTEGRATED DATA-DRIVEN DRUG DISCOVERY AND DEVELOPMENT PLATFORMS - LILLY HAS THE RIGHT...

EVTCY : 22.9600 (-0.04%)
EVO : 5.08 (-2.87%)
Evotec Expands Neuroscience Collaboration with Bristol Myers Squibb to Include New Targeted Protein Degradation Approach

- EXPANSION LEVERAGES A PROPRIETARY EVOTEC PLATFORM IN THE FIELD OF TARGETED PROTEIN DEGRADATION TO TACKLE SELECTED TARGETS WITH RELEVANCE FOR A RANGE OF NEURODEGENERATIVE CONDITIONS - EVOTEC RECEIVES...

EVTCY : 22.9600 (-0.04%)
BMY : 44.81 (-8.29%)
Evotec Receives US$ 18 M Grant for Women's Health

- GRANT WILL SUPPORT FULLY INTEGRATED DRUG DISCOVERY PROGRAMME FROM SCREENING TO PRE-CLINICAL DEVELOPMENT CANDIDATE - PROJECT LEVERAGES EVOTEC'S WOMEN'S HEALTH PLATFORM AND AI/ML MOLECULAR DESIGN TOOLS...

EVTCY : 22.9600 (-0.04%)
Evotec and EQRx Announce Integrated Drug Discovery and Development Partnership

- EQRX TO LEVERAGE EVOTEC'S UNIQUE DATA-DRIVEN INTEGRATED DRUG DISCOVERY AND DEVELOPMENT ACCELERATOR PLATFORM - PARTNERSHIP AIMS TO BUILD UP JOINTLY OWNED PIPELINE TO DELIVER INNOVATIVE, AFFORDABLE AND...

EVTCY : 22.9600 (-0.04%)
EVO : 5.08 (-2.87%)
CMLTU : 8.87 (-6.53%)
Evotec Reaches Programme Designations in Neuroscience Collaboration with Bristol Myers Squibb

- THE DESIGNATION OF ADDITIONAL PROGRAMMES BY BRISTOL MYERS SQUIBB TRIGGERED PAYMENTS OF IN TOTAL US$ 40 M TO EVOTEC HAMBURG, GERMANY / ACCESSWIRE / November 10, 2021 / Evotec SE (Frankfurt Stock Exchange:EVT,...

EVTCY : 22.9600 (-0.04%)
EVO.AX : 0.675 (unch)
BMY : 44.81 (-8.29%)
Evotec SE Announces Placement of Its Public Offering of American Depositary Shares

HAMBURG, GERMANY / ACCESSWIRE / 3 November 2021 / Evotec SE's (Frankfurt Stock Exchange; EVT, MDAX/TecDAX, ISIN: DE0005664809, WKN 566480) management board today decided - with the approval of its supervisory...

EVTCY : 22.9600 (-0.04%)
Evotec SE To Announce Results for the First Nine Months 2021 On 11 November 2021

HAMBURG, GERMANY / ACCESSWIRE / November 3, 2021 / Evotec SE (Frankfurt Stock Exchange:EVT, MDAX/TecDAX, ISIN: DE0005664809) will announce its financial results for the first nine months 2021 on Thursday,...

EVTCY : 22.9600 (-0.04%)
Evotec SE: Announces Launch of Public Offering of American Depositary Shares

HAMBURG, GERMANY / ACCESSWIRE / October 26, 2021 / Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809) announced today that it has commenced a public offering in the United States...

EVTCY : 22.9600 (-0.04%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 56% Buy with a Weakest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

EVOTEC is a leader in the discovery and development of novel small molecule drugs. They have established a powerful platform that is applicable to targets across all therapeutic areas and has specific expertise in the area of Central Nervous System related diseases where it is building a pipeline of...

See More

Key Turning Points

3rd Resistance Point 23.0602
2nd Resistance Point 23.0401
1st Resistance Point 23.0001
Last Price 22.9600
1st Support Level 22.9400
2nd Support Level 22.9199
3rd Support Level 22.8799

See More

52-Week High 26.5700
Last Price 22.9600
Fibonacci 61.8% 21.8533
Fibonacci 50% 20.3962
Fibonacci 38.2% 18.9392
52-Week Low 14.2225

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar